Mike Bonney - Kaleido Biosciences Chairman of the Board, CEO
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Chairman
Mr. Mike Bonney is the Chairman of the Board, Chief Executive Officer of the Company. Mike Bonney joins the Kaleido team from Cubist Pharmaceuticals, where he served as CEO and Director and led it to become the worlds leading antibiotic company, which was acquired by Merck for 9.5 billion in 2015. At Cubist, Bonney oversaw the development and release of the antibiotic Cubicin the most successful launch of an antibiotic in American history. Prior to Cubist, Bonney worked at Biogen, where he launched one of the leading MS drugs in the United States, Avonex, which experienced tremendous commercial success. Mike chairs the Board of Alnylam Pharmaceuticals and the Bates College Board of Trustees. He also serves as a board member of CELGENE, the Whitehead institute for Biomedical Research and others. Recently, Bonney was a national finalist in Ernst Youngs Entrepreneur of the year, and was recognized as the Top CEO in Massachusetts by the Boston Globe. In 2011, he was also one of six executives nationwide to be named Best CEO in the Country by MarketWatch.
| Phone | 617 674 9000 |
| Web | https://kaleido.com |
Kaleido Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Sumit Mazumder | Instil Bio | 69 | |
| Bruce Harker | Instil Bio | N/A | |
| Hoyoung Huh | CytomX Therapeutics | 47 | |
| Alan Danson | Instil Bio | N/A | |
| William Ringo | Assembly Biosciences | 71 | |
| Sean DPHIL | CytomX Therapeutics | 57 | |
Management Performance
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 |
Kaleido Biosciences Leadership Team
Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Geoffrey Maltzahn, President Co-Founder | ||
| Jeremy Buzzard, Senior Vice President - Corporate Development | ||
| Johannes Vlieg, Chief Scientific Officer | ||
| Grady Burnett, Director | ||
| Mark Wingertzahn, VP Devel | ||
| Bonnie Bassler, Director | ||
| Jeffery Moore, Senior Vice President - Finance & Administration | ||
| Clare Fisher, Chief Business Officer | ||
| LLM JD, Chief Advisor | ||
| Jerald Korn, General Counsel, Corporate Secretary | ||
| Mike Bonney, Chairman of the Board, CEO | ||
| John Sculley, Director | ||
| Ruth ThieroffEkerdt, Chief Medical Officer | ||
| Theo MelasKyriazi, Independent Director | ||
| Kimberly Hocknell, VP Operations |
Kaleido Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |